Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold, Lowers Price Target to $23

Stifel Nicolaus downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Buy to Hold and lowers the price target from $55 to $23.

Benzinga · 11/07/2019 11:49

Stifel Nicolaus downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Buy to Hold and lowers the price target from $55 to $23.